338 related articles for article (PubMed ID: 30575604)
21. Mesonephric Adenocarcinoma of the Uterine Corpus: A Case Report and Diagnostic Pitfall.
Kim SS; Nam JH; Kim GE; Choi YD; Choi C; Park CS
Int J Surg Pathol; 2016 Apr; 24(2):153-8. PubMed ID: 26510860
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
23. GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.
Howitt BE; Emori MM; Drapkin R; Gaspar C; Barletta JA; Nucci MR; McCluggage WG; Oliva E; Hirsch MS
Am J Surg Pathol; 2015 Oct; 39(10):1411-9. PubMed ID: 26135559
[TBL] [Abstract][Full Text] [Related]
24. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
25. Mesonephric Adenocarcinoma of the Uterine Corpus: A Report on 2 Cases With Comparison to Its Cervical Counterpart.
Liang Y; Shi H; Zhu X; Yu M; Zhang X
Int J Gynecol Pathol; 2020 Nov; 39(6):546-551. PubMed ID: 31985582
[TBL] [Abstract][Full Text] [Related]
26. Mucinous Tumor Coexisting With Mesonephric-like Proliferation/Tumor in the Ovary: A Novel Association.
Nilforoushan N; Liu L; Cheang G; Sui AC; Andersen J; Finkelman BS; Liu Y; Nasseri-Nik N; Vang R; Ronnett BM; Song W; Xing D
Am J Surg Pathol; 2022 Aug; 46(8):1095-1105. PubMed ID: 35405716
[TBL] [Abstract][Full Text] [Related]
27. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
28. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases.
Mansor S; McCluggage WG
Int J Gynecol Pathol; 2014 Sep; 33(5):470-6. PubMed ID: 25083962
[TBL] [Abstract][Full Text] [Related]
29. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
30. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion.
Yemelyanova A; Mao TL; Nakayama N; Shih IeM; Kurman RJ
Am J Surg Pathol; 2008 Dec; 32(12):1800-6. PubMed ID: 18779727
[TBL] [Abstract][Full Text] [Related]
31. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
Rabban JT; McAlhany S; Lerwill MF; Grenert JP; Zaloudek CJ
Am J Surg Pathol; 2010 Feb; 34(2):137-46. PubMed ID: 20061933
[TBL] [Abstract][Full Text] [Related]
32. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-β.
Kenny SL; McBride HA; Jamison J; McCluggage WG
Am J Surg Pathol; 2012 Jun; 36(6):799-807. PubMed ID: 22456609
[TBL] [Abstract][Full Text] [Related]
33. Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas.
McFarland M; Quick CM; McCluggage WG
Histopathology; 2016 Jun; 68(7):1013-20. PubMed ID: 26484981
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study.
Pors J; Segura S; Chiu DS; Almadani N; Ren H; Fix DJ; Howitt BE; Kolin D; McCluggage WG; Mirkovic J; Gilks B; Park KJ; Hoang L
Am J Surg Pathol; 2021 Apr; 45(4):498-506. PubMed ID: 33165093
[TBL] [Abstract][Full Text] [Related]
35. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
Diebold J; Seemüller F; Löhrs U
Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
[TBL] [Abstract][Full Text] [Related]
36. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
37. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
[TBL] [Abstract][Full Text] [Related]
38. Mesonephric-like adenocarcinoma harbours characteristic copy number variations and a distinct DNA methylation signature closely related to mesonephric adenocarcinoma of the cervix.
Kommoss FK; Lee CH; Tessier-Cloutier B; Gilks CB; Stewart CJ; von Deimling A; Köbel M
J Pathol; 2024 Jan; 262(1):4-9. PubMed ID: 37850576
[TBL] [Abstract][Full Text] [Related]
39. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
40. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
